The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

综上所述，对神经病理性疼痛的评估和管理需要一个综合的方法，包括全面的临床评估、症状分析和量表评估。随着研究的不断深入，我们相信将会有更多更精确的评估工具出现，帮助医生更好地了解和处理这一复杂的病症。

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...